Physician profile
Phong D Dang
NPI 1447394465
$1,790.32
in general payments reported to CMS, 2019-2025
28 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $97.55 · 2021: $61.79 · 2022: $256 · 2023: $113 · 2024: $296 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $255.34 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $187.67 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $170.87 | 2019-2025 | |
| Lilly USA, LLC | $151.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $137.74 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $104.47 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $95.60 | 2023-2025 | Rexulti, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $88.14 | 2022-2025 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $78.73 | 2019-2025 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $72.24 | 2022 | |
| Exact Sciences Corporation | $48.13 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $39.88 | 2021-2022 | |
| Mylan Specialty L.P. | $39.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.12 | 2022-2024 | |
| Biogen, INC. | $35.49 | 2023-2024 | Skyclarys, Skyclarys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $32.29 | 2022 | |
| Merck Sharp & Dohme LLC | $29.44 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Harmony Biosciences LLC | $21.77 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.33 | 2022 | |
| Mallinckrodt Hospital Products INC. | $21.19 | 2024 | Acthar |
| Allergan, INC. | $21.10 | 2019 | |
| Acadia Pharmaceuticals INC | $17.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.57 | 2024 | Spravato |
| Phathom Pharmaceuticals, INC. | $15.48 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.06 | 2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $13.91 | 2020 | |
| Dexcom, INC. | $12.98 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phong Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.